MTOR and non-Hodgkin lymphoma: Recently, the mammalian target of rapamycin (mTOR) inhibitor everolimus was shown to act synergistically with gemcitabine or paclitaxel for treatment against non-Hodgkin lymphoma (NHL) cell lines [59].